TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35610603

Group type: EXPERIMENTAL
Intervention: Healthy APproach to weIght management and Food in Eating Disorders (HAPIFED)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Cognitive Behavioural Therapy‐ Enhanced (CBT‐E)
Number of subjects: 98
Study: 33432016

Group type: EXPERIMENTAL
Intervention: Self-administered survey on waste management awareness
Number of subjects: 2720
Study: 34491428

Group type: EXPERIMENTAL
Intervention: Nasal cannula under the surgical mask
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Oxygen mask under the surgical mask
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Oxygen mask over the surgical mask
Number of subjects: 24
Study: 34243076

Group type: EXPERIMENTAL
Intervention: Veliparib (120 mg orally BID) with carboplatin (AUC 6) and paclitaxel (80 mg/m2)
Number of subjects: 413

Group type: COMPARATOR
Intervention: Placebo with carboplatin (AUC 6) and paclitaxel (80 mg/m2)
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: Veliparib (300 mg BID, increasing to 400 mg BID if tolerated)
Number of subjects: 413

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 413
Study: 35681130

Group type: EXPERIMENTAL
Intervention: teen Mental Health First Aid (tMHFA)
Number of subjects: 1624

Group type: COMPARATOR
Intervention: Physical first aid training (control)
Number of subjects: 1624
Study: 32601853

Group type: EXPERIMENTAL
Intervention: Expressive writing group (n = 56)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Prolonged expressive writing group (n = 56)
Number of subjects: 112
Study: 33836814

Group type: EXPERIMENTAL
Intervention: Single-injection ultrasound-guided thoracic paravertebral block (US-TPVB) with 20 ml of 0.25% ropivacaine
Number of subjects: 88

Group type: COMPARATOR
Intervention: Oblique subcostal transversus abdominis plane (TAP) block with 20 ml of 0.25% ropivacaine
Number of subjects: 88

Group type: COMPARATOR
Intervention: Local anesthetic infiltration (LAI) with 40 ml of 0.25% ropivacaine
Number of subjects: 88
Study: 33074110

Group type: EXPERIMENTAL
Intervention: Anulom Vilom Pranayama (AVP)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Diaphragmatic Breathing Exercises (DBE)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Kapal Bhati Pranayama (KBP)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Pursed-Lip Breathing (PLB)
Number of subjects: 60
Study: 36066078

Group type: EXPERIMENTAL
Intervention: Indacaterol (27.5 μg) plus glycopyrrolate (15.6 μg) twice daily for 12 weeks
Number of subjects: 535

Group type: COMPARATOR
Intervention: Placebo twice daily for 12 weeks
Number of subjects: 535

Group type: EXPERIMENTAL
Intervention: Indacaterol plus glycopyrrolate
Number of subjects: 535

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 535
Study: 33554616

Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 4401

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4401
Study: 32176061

Group type: EXPERIMENTAL
Intervention: Apatinib combined with carboplatin-paclitaxel or concurrent chemo-brachytherapy (CCBT)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Chemotherapy alone or CCBT
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Apatinib combined with chemotherapy or CCBT
Number of subjects: 52
Study: 35501515

Group type: EXPERIMENTAL
Intervention: Post-infusion cooling time (PICT) of 45 min
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Post-infusion cooling time (PICT) of 20 min
Number of subjects: 91

Group type: COMPARATOR
Intervention: Standard post-infusion cooling time (PICT) of 90 min
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Dean scale assessment
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: CTCAE assessment
Number of subjects: 91
Study: 34312774

Group type: EXPERIMENTAL
Intervention: Tamoxifen‐gonadotropin
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Letrozole‐gonadotropin
Number of subjects: 134

Group type: COMPARATOR
Intervention: Gonadotropin only
Number of subjects: 134
Study: 35037319

Group type: EXPERIMENTAL
Intervention: Chat-based support (CBS, n=304)
Number of subjects: 679

Group type: COMPARATOR
Intervention: Text-based support (TBS, n=375)
Number of subjects: 679

Group type: EXPERIMENTAL
Intervention: Engaged participants (both CBS and TBS)
Number of subjects: 679
Study: 33919195

Group type: EXPERIMENTAL
Intervention: Deep Dry Needling (DDN)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Ischemic Compression Technique (ICT)
Number of subjects: 34
Study: 36348385

Group type: EXPERIMENTAL
Intervention: Rucaparib 600 mg twice daily as maintenance therapy
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Rucaparib 600 mg twice daily as treatment
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Rucaparib (both maintenance and treatment)
Number of subjects: 51
Study: 33588088

Group type: EXPERIMENTAL
Intervention: CRRT at 70 ml/kg/h
Number of subjects: 30

Group type: COMPARATOR
Intervention: CRRT at 35 ml/kg/h
Number of subjects: 30
Study: 32134289

Group type: EXPERIMENTAL
Intervention: Performance feedback on writing fluency
Number of subjects: 0
Study: 35123660

Group type: EXPERIMENTAL
Intervention: Baricitinib (4 mg) once daily for up to 14 days plus standard of care
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo plus standard of care
Number of subjects: 101
Study: 33128066

Group type: EXPERIMENTAL
Intervention: PrEP (Preexposure prophylaxis) at 70% coverage
Number of subjects: 11245

Group type: COMPARATOR
Intervention: Control group (no PrEP)
Number of subjects: 11245
Study: 32552774

Group type: EXPERIMENTAL
Intervention: Oral fluralaner (Bravecto®) administered at a minimum dose of 25 mg/kg body weight, one time on Day 0.
Number of subjects: 20
Study: 35731547

Group type: EXPERIMENTAL
Intervention: Aim2Be mHealth app
Number of subjects: 214
Study: 33527377

Group type: EXPERIMENTAL
Intervention: Hands-on demonstration of a class IV composite restoration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Video-supported demonstration of a class IV composite restoration
Number of subjects: 0
Study: 35853489

Group type: EXPERIMENTAL
Intervention: Monthly injection (AM)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Sham (SM)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Injection every other month (AEOM)
Number of subjects: 113
Study: 34031331

Group type: EXPERIMENTAL
Intervention: Pelvic Floor Muscle Exercise (PFME) intervention
Number of subjects: 30
Study: 32089798

Group type: EXPERIMENTAL
Intervention: Podcast
Number of subjects: 60

Group type: COMPARATOR
Intervention: Written
Number of subjects: 60
Study: 36276114

Group type: EXPERIMENTAL
Intervention: 0.375% ropivacaine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 60
Study: 33027403

Group type: EXPERIMENTAL
Intervention: Weekly text messages
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Biweekly text messages
Number of subjects: 156

Group type: COMPARATOR
Intervention: Standard treatment (Control)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Text message intervention (both weekly and biweekly)
Number of subjects: 156
Study: 36578007

Group type: EXPERIMENTAL
Intervention: Phonological intervention
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Visual-attentional intervention
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Cross-modal intervention
Number of subjects: 120

Group type: COMPARATOR
Intervention: Business-as-usual (baseline)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Follow-up assessment (2 months post-intervention)
Number of subjects: 120
Study: 32162321

Group type: EXPERIMENTAL
Intervention: Wound protector
Number of subjects: 212

Group type: COMPARATOR
Intervention: Standard surgical drapes
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Wound protector (subanalysis)
Number of subjects: 212

Group type: COMPARATOR
Intervention: Standard surgical drapes (subanalysis)
Number of subjects: 212
Study: 35643951

Group type: EXPERIMENTAL
Intervention: High-dose prednisolone (HDP) 60 mg daily (tapered to 0 mg within 12 weeks)
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: Low-dose prednisolone (LDP) 10 mg daily (tapered to 0 mg within 12 weeks)
Number of subjects: 395

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: High-dose prednisolone (HDP)
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: Low-dose prednisolone (LDP)
Number of subjects: 395
Study: 32522106

Group type: EXPERIMENTAL
Intervention: Docetaxel-based chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: 5-fluorouracil/leucovorin (5-FU/LV) chemotherapy
Number of subjects: 0
Study: 35041742

Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Number of subjects: 112

Group type: COMPARATOR
Intervention: Bupivacaine with dexamethasone
Number of subjects: 112
Study: 33296079

Group type: EXPERIMENTAL
Intervention: High-protein enteral nutrition (63 or 100 g/L protein) for ≤28 days
Number of subjects: 120

Group type: COMPARATOR
Intervention: Usual practice enteral nutrition (lower protein doses)
Number of subjects: 120
Study: 35023050

Group type: EXPERIMENTAL
Intervention: Heavy load (HEV)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Moderate load (MOD)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Light load (LIT)
Number of subjects: 16
Study: 32698959

Group type: EXPERIMENTAL
Intervention: Mediterranean diet (Med‐D)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Western-type diet (Control‐D)
Number of subjects: 29
Study: 35274295

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 165
Study: 32151511

Group type: EXPERIMENTAL
Intervention: Bilateral Transversus Thoracis Muscle Plane Block (TTP group)
Number of subjects: 100
Study: 33051948

Group type: EXPERIMENTAL
Intervention: Patients with delirium (n = 17)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Patients without delirium (n = 53)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Overall findings
Number of subjects: 70
Study: 33075434

Group type: EXPERIMENTAL
Intervention: Cognitive reappraisal
Number of subjects: 119

Group type: COMPARATOR
Intervention: Just-play (no regulation)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Resting-state HRV
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: State HRV
Number of subjects: 119
Study: 36205850

Group type: EXPERIMENTAL
Intervention: Injunctive norm message
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Descriptive norm message
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Both messages
Number of subjects: 205

Group type: COMPARATOR
Intervention: Neither message
Number of subjects: 205
Study: 32612574

Group type: EXPERIMENTAL
Intervention: Combined Oral Contraceptive (COC)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Contraceptive Vaginal Ring (CVR)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control
Number of subjects: 24
Study: 34797506

Group type: EXPERIMENTAL
Intervention: Apalutamide + ADT
Number of subjects: 455
Study: 33043969

Group type: EXPERIMENTAL
Intervention: Vesatolimod (1-12 mg)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Vesatolimod (6 mg)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 35396289

Group type: EXPERIMENTAL
Intervention: Smartphone-based photoplethysmography application assessment
Number of subjects: 236

Group type: COMPARATOR
Intervention: Modified Allen's test (MAT)
Number of subjects: 236
Study: 34216380

Group type: EXPERIMENTAL
Intervention: EORTC QLU-C10D value set generation
Number of subjects: 1010
Study: 32721009

Group type: EXPERIMENTAL
Intervention: Intravenous acetaminophen, 1 g, starting at the beginning of surgery and repeated every 6 hours until 48 postoperative hours or hospital discharge
Number of subjects: 570

Group type: COMPARATOR
Intervention: Normal saline placebo
Number of subjects: 570

Group type: EXPERIMENTAL
Intervention: Intravenous acetaminophen
Number of subjects: 570
Study: 35873893

Group type: EXPERIMENTAL
Intervention: High-dose vitamin C infusion (1.5 g/6 h for 4 days)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (100 mg vitamin C/day for 4 days)
Number of subjects: 40
Study: 32370588

Group type: EXPERIMENTAL
Intervention: ABC pathway adherence
Number of subjects: 0

Group type: COMPARATOR
Intervention: ABC pathway adherence (multimorbidity group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: ABC pathway adherence (polypharmacy group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: ABC pathway adherence (hospitalization group)
Number of subjects: 0
Study: 33177370

Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Attention Control (video on a tablet)
Number of subjects: 60
Study: 32079967

Group type: EXPERIMENTAL
Intervention: Ten Top Tips (10TT) intervention
Number of subjects: 0
Study: 36371162

Group type: EXPERIMENTAL
Intervention: MPVC (MSmonitor-Plus and Video calling Care)
Number of subjects: 208

Group type: COMPARATOR
Intervention: CAU (Care as Usual)
Number of subjects: 208
Study: 34578862

Group type: EXPERIMENTAL
Intervention: 1-Kestose supplementation (10 g/day for 12 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1-Kestose supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 0
Study: 32833935

Group type: EXPERIMENTAL
Intervention: Multifactorial, pharmacist-delivered phone-based telehealth intervention
Number of subjects: 281

Group type: COMPARATOR
Intervention: Education control
Number of subjects: 281
Study: 35688801

Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation (A-tDCS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cathodal transcranial direct current stimulation (C-tDCS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 0
Study: 32761611

Group type: EXPERIMENTAL
Intervention: Trimodal prehabilitation program (4 weeks)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Control group managed according to enhanced recovery after surgery principles supplemented by nutritional care
Number of subjects: 149
Study: 35357405

Group type: EXPERIMENTAL
Intervention: Printed chart
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Mobile phone app
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Website test
Number of subjects: 121
Study: 33422499

Group type: EXPERIMENTAL
Intervention: PEAK PlasmaBlade™ (PPB)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Conventional diathermy
Number of subjects: 108
Study: 35081757

Group type: EXPERIMENTAL
Intervention: Narrative messages
Number of subjects: 300

Group type: COMPARATOR
Intervention: Statistics messages
Number of subjects: 300
Study: 33226202

Group type: COMPARATOR
Intervention: Protocol A (120 kVp and standard weight‐adapted CM dose)
Number of subjects: 126
Study: 32257154

Group type: EXPERIMENTAL
Intervention: Community activism/mobilisation portion of Indashyikirwa, based on SASA! program model.
Number of subjects: 2800
Study: 35172871

Group type: EXPERIMENTAL
Intervention: HSM plus original antihypertensive regimen
Number of subjects: 400

Group type: COMPARATOR
Intervention: Control (original antihypertensive regimen only)
Number of subjects: 400
Study: 616874253

Group type: EXPERIMENTAL
Intervention: Ulinastatin
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 30
Study: 36098658

Group type: EXPERIMENTAL
Intervention: Participants who developed T2D (1,614 individuals)
Number of subjects: 2499

Group type: COMPARATOR
Intervention: Participants who remained without diabetes (885 individuals)
Number of subjects: 2499
Study: 32619274

Group type: EXPERIMENTAL
Intervention: Reciproc protocol
Number of subjects: 120

Group type: COMPARATOR
Intervention: Manual protocol
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Low-income persons
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Both protocols
Number of subjects: 120
Study: 34839470

Group type: EXPERIMENTAL
Intervention: Silver nylon dressing
Number of subjects: 649

Group type: COMPARATOR
Intervention: Gauze dressing
Number of subjects: 649
Study: 34462279

Group type: EXPERIMENTAL
Intervention: Levonorgestrel 52 mg intrauterine system (LNG‐IUS 52 mg)
Number of subjects: 208

Group type: COMPARATOR
Intervention: Hysteroscopic niche resection
Number of subjects: 208
Study: 32952045

Group type: EXPERIMENTAL
Intervention: Delegation to MFAs with extended qualification (EVA, VERAH, VERAH Plus)
Number of subjects: 2404

Group type: COMPARATOR
Intervention: Delegation to standard qualified MFAs
Number of subjects: 2404
Study: 33678048

Group type: EXPERIMENTAL
Intervention: Minding the Baby® (MTB) home visiting program
Number of subjects: 97
Study: 32652300

Group type: EXPERIMENTAL
Intervention: Megestrol acetate (40 mg for 14 days) + Metformin (1000 mg daily for 3 months)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Megestrol acetate (40 mg for 14 days) + Placebo
Number of subjects: 60
Study: 32148744

Group type: EXPERIMENTAL
Intervention: Conventional rehabilitation with video-game based therapy for 8 weeks, 5 sessions per week
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional rehabilitation (control group) for 8 weeks, 5 sessions per week
Number of subjects: 50
Study: 34757164

Group type: EXPERIMENTAL
Intervention: Isometric height-indexed LAVmax
Number of subjects: 986

Group type: EXPERIMENTAL
Intervention: Allometric height-indexed LAVmax
Number of subjects: 986

Group type: EXPERIMENTAL
Intervention: Height-indexed LAVmin
Number of subjects: 986

Group type: EXPERIMENTAL
Intervention: LAVmax > 22.1 mL/m1.72
Number of subjects: 986
Study: 33245533

Group type: EXPERIMENTAL
Intervention: tamsulosin + mirabegron 50 mg
Number of subjects: 568

Group type: COMPARATOR
Intervention: tamsulosin + placebo
Number of subjects: 568
Study: 32870158

Group type: EXPERIMENTAL
Intervention: WebMAP Mobile (WMM) intervention
Number of subjects: 143
Study: 35820740

Group type: EXPERIMENTAL
Intervention: Manometry-guided therapeutic thoracentesis
Number of subjects: 61
Study: 34024687

Group type: EXPERIMENTAL
Intervention: Burn injury
Number of subjects: 9099

Group type: COMPARATOR
Intervention: No burn injury (Control)
Number of subjects: 9099
Study: 32008782

Group type: EXPERIMENTAL
Intervention: ACR1.2 (cluster remover take‐off milk flow threshold of 1.2 kg/min)
Number of subjects: 689

Group type: COMPARATOR
Intervention: ACR0.8 (cluster remover take‐off milk flow threshold of 0.8 kg/min)
Number of subjects: 689

Group type: EXPERIMENTAL
Intervention: ACR1.2
Number of subjects: 689

Group type: COMPARATOR
Intervention: ACR0.8
Number of subjects: 689
Study: 34743348

Group type: EXPERIMENTAL
Intervention: FPC 6.75 mg Fe IV predialyzer
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: FPC 6.75 mg Fe IV postdialyzer
Number of subjects: 27

Group type: COMPARATOR
Intervention: FPC 2 μM (110 μg Fe/L of hemodialysate)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: FPC IV infusion of 6.75 mg iron during 3 hours of HD
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Overall bioequivalence assessment
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Safety of IV FPC
Number of subjects: 27
Study: 34092587

Group type: EXPERIMENTAL
Intervention: Fascial treatment (FT)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Manual therapy (MT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: No intervention (control group, CG)
Number of subjects: 60
Study: 35688442

Group type: EXPERIMENTAL
Intervention: HTX‐011 (400 mg bupivacaine/12 mg meloxicam) with multimodal analgesic regimen (preoperative acetaminophen, celecoxib, pregabalin, and postoperative acetaminophen and celecoxib)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: HTX‐011 with MMA regimen
Number of subjects: 51
Study: 33205642

Group type: EXPERIMENTAL
Intervention: Patients who died in hospital due to CDI (group A)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Patients who survived (group B)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Renal failure
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: WBC count
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Lower albumin level
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Advanced age
Number of subjects: 180
Study: 33164410

Group type: EXPERIMENTAL
Intervention: Xiaoji Recipe + Rosuvastatin Calcium 10 mg·d(‐1)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Rosuvastatin Calcium 20 mg·d(‐1)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Both groups (Xiaoji and control)
Number of subjects: 125
Study: 36031894

Group type: EXPERIMENTAL
Intervention: Hypnosis intervention for couples (8-week duration)
Number of subjects: 16
Study: 32828663

Group type: EXPERIMENTAL
Intervention: Augmented reality headset
Number of subjects: 30

Group type: COMPARATOR
Intervention: Laptop screen
Number of subjects: 30
Study: 32078394

Group type: EXPERIMENTAL
Intervention: CASH‐AA + MIP
Number of subjects: 145

Group type: COMPARATOR
Intervention: CASH‐AA Only
Number of subjects: 145
Study: 32621730

Group type: EXPERIMENTAL
Intervention: Generalized obesity
Number of subjects: 10037

Group type: EXPERIMENTAL
Intervention: Abdominal obesity
Number of subjects: 10037

Group type: EXPERIMENTAL
Intervention: Non-obese adolescents
Number of subjects: 10037

Group type: COMPARATOR
Intervention: Private vs Government schools
Number of subjects: 10037
Study: 35034510

Group type: EXPERIMENTAL
Intervention: Working-memory training (WMT)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Neurofeedback (Slow Cortical Potential and Live Z-score)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 202
Study: 34783626

Group type: EXPERIMENTAL
Intervention: Blended Rational Emotive Behavior Therapy (REBT) for 12 weeks (2 hours weekly)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Waitlisted group (control)
Number of subjects: 83
Study: 35723940

Group type: EXPERIMENTAL
Intervention: Hydrogen peroxide 35% solution
Number of subjects: 33

Group type: COMPARATOR
Intervention: Cryotherapy
Number of subjects: 33
Study: 32205449

Group type: EXPERIMENTAL
Intervention: HIPEC
Number of subjects: 538

Group type: COMPARATOR
Intervention: No HIPEC (Control)
Number of subjects: 538
Study: 33781392

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (no ACT)
Number of subjects: 70